Korro Bio KRRO
NASDAQ KRRO
$14.41 -1.32 (-8.39%)
At close: Nov 11, 2026 · 4:00 PM EST

Korro Bio (KRRO) Asset Writedowns and Impairment (2025)

Updated

Korro Bio (KRRO) recorded Asset Writedowns and Impairment of $15 million in Q4 2025.

Analysis

Korro Bio (KRRO) Asset Writedowns and Impairment (2025) Analysis & Trends

For FY2025, Korro Bio reported Asset Writedowns and Impairment of $30.9 million.

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn
5 Novartis Ag 311.58 Bn 285.16 Bn -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn
10 Korro Bio 281.05 Mn -128.11 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2025 15.00 Mn
API Access

Korro Bio Asset Writedowns and Impairment API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=asset-writedowns-and-impairment&ticker=KRRO&period=max&api_key=YOUR_API_KEY